IBR854 / Imbioray Bio - LARVOL DELTA

A study to evaluate the safety and primary efficacy of the combination therapy of recombinant human IL-21 oncolytic vaccinia virus injection (hV01) and ready-to-use CAR-raNK cells (IBR854) in patients with advanced malignant solid tumors (ChiCTR) - P=N/A | N=5 | Completed | Sponsor: Xiamen Humanity Hospital; Xiamen Humanity Hospital

New trial • Gynecologic Cancers • Head and Neck Cancer • Liver Cancer • Oncology • Pancreatic Cancer • Sarcoma • Solid Tumor

A phase I clinical trial of 5T4-antibody NK cell conjugation (IBR854 Injection) in patients with advanced solid tumor (ESMO 2025) - P1 | "Conclusions Single-agent IBR854 injection showed safe and well tolerated in advanced solid tumor patients. We will conduct further clinical studies on IBR854 injection in a larger cohort of patients or in combination with other agents against advanced solid tumors."

Clinical • Metastases • P1 data • Breast Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma

A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd.

New P2 trial • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

InBio completed nearly RMB 100 million in Series A+ financing, led by Huarui Investment [Google translation] (Sohu.com) - "According to the news from the investment community on January 22, Inbio (Hangzhou) Biopharmaceutical Co., Ltd...recently completed a round of A+ financing of nearly 100 million yuan. This round of financing was led by Huarui Investment, followed by Tailong Investment, Sunzi Technology, Huayi Capital, and Binjiang 5050 Fund. This round of financing is mainly used for the global FIC (first-in-class) universal natural killer cell therapy, that is, the registration clinical projects of innovative biological products such as IBR854, IBR733, IBR822, and IBR900, and to accelerate the launch of a series of original innovative peripheral blood-derived, non-viral vector, non-gene-edited spot universal immune-tamed NK/CAR-raNK and tiNK cell products."

Financing • Hematological Malignancies • Solid Tumor

Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Gastrointestinal Cancer • Oncology • Solid Tumor

Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd.

Metastases • New P1 trial • Gastrointestinal Cancer • Oncology • Solid Tumor

Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Shanghai East Hospital | Trial completion date: Aug 2022 ➔ May 2023 | Trial primary completion date: Aug 2022 ➔ Apr 2023

Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • CD4 • ER • HER-2 • IL10 • IL2 • IL6 • NCAM1 • PGR

Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Shanghai East Hospital | N=136 ➔ 56

Enrollment change • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • CD4 • ER • HER-2 • IL10 • IL2 • IL6 • NCAM1 • PGR